Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1Phase 1/2 1Phase 1 1

Status

Completed 4

Sponsor Class

OTHER 36NIH 10INDUSTRY 4NETWORK 1

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 2CNS 2Head & Neck 1Breast 1

Conditions

Brain Neoplasms 2Lung Neoplasms 1Head and Neck Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

pembrolizumab 1032Carboplatin 969Paclitaxel 942Gemcitabine 799Cisplatin 755Docetaxel 698Bevacizumab 638Nivolumab 520Pemetrexed 507Capecitabine 475Cyclophosphamide 471Fluorouracil 425Dexamethasone 410Rituximab 391Oxaliplatin 352Injections 345Trastuzumab 313atezolizumab 311Cetuximab 291Leucovorin 289Irinotecan 271130-nm albumin-bound paclitaxel 256Prednisone 251Ipilimumab 244Doxorubicin 241Lenalidomide 231Fulvestrant 226fludarabine 217durvalumab 211Erlotinib Hydrochloride 196

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × alovudine × Clear all
NCT00453362 2017-03-31

A Study of Changes in FDG- and FLT-PET Imaging in Patients With Non-Small Cell Lung Cancer Following Treatment With Erlotinib

Genentech, Inc.

Phase 1/2 Completed
88 enrolled 18 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01480583 2016-07-13

GRABM-B

Angiochem Inc

Phase 2 Completed
85 enrolled
BreastCNS

Brain Neoplasms, Breast Neoplasms

NCT00847509 2013-09-27

FLT101

Siemens Molecular Imaging

Phase NA Completed
49 enrolled 4 charts
Head & NeckThoracic

Head and Neck Neoplasms, Lung Neoplasms

NCT00553748 2008-07-03

Phase I, Open Label, Single Center Safety Study of [F-18]FLT

Siemens Molecular Imaging

Phase 1 Completed
11 enrolled
CNS

Brain Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡